(Q47605895)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28980701%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

title

Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28980701%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28980701%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Helen A Shih

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28980701%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Daniel P Cahill

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28980701%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

author name string

Ovidiu C Andronesi

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28980701%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

language of work or name

English

0 references

publication date

5 October 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28980701%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28980701%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

volume

123

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28980701%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

issue

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28980701%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

page(s)

4535-4546

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28980701%20AND%20SRC:MED&resulttype=core&format=json

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.

1 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

The consensus coding sequences of human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Cellular defense against UVB-induced phototoxicity by cytosolic NADP(+)-dependent isocitrate dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Expanding chemical biology of 2-oxoglutarate oxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Role of NADP+-dependent isocitrate dehydrogenase (NADP+-ICDH) on cellular defence against oxidative injury by gamma-rays

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

D-2-hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

ROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic Strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

IDH mutation impairs histone demethylation and results in a block to cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Insulator dysfunction and oncogene activation in IDH mutant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Mutations in CIC and FUBP1 contribute to human oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Altered telomeres in tumors with ATRX and DAXX mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Alteration of isocitrate dehydrogenase following acute ischemic injury as a means to improve cellular energetic status in neuroadaptation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Noninvasive Assessment of IDH Mutational Status in World Health Organization Grade II and III Astrocytomas Using DWI and DSC-PWI Combined with Conventional MR Imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Detection of 2-hydroxyglutarate in brain tumors by triple-refocusing MR spectroscopy at 3T in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

In vivo detection of 2-hydroxyglutarate in brain tumors by optimized point-resolved spectroscopy (PRESS) at 7T.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Chemotherapy for low-grade glioma: when, for whom, which regimen?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

A vaccine targeting mutant IDH1 induces antitumour immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

inferred from DOI database lookup

7 January 2021

based on heuristic

Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

inferred from DOI database lookup

7 January 2021

based on heuristic

Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31039

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.31039

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28980701%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

1 reference